文献速递浆细胞疾病造血干细胞移植与细胞治疗

新诊断多发性骨髓瘤自体干细胞移植后来那度胺维持治疗:一项荟萃分析

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.
PubMed 文献 · J Clin Oncol · 2017-07-25

该荟萃分析纳入三项随机对照试验共1208例新诊断多发性骨髓瘤患者,比较自体干细胞移植后来那度胺维持与安慰剂或观察。来那度胺组中位无进展生存52.8个月 vs 安慰剂或观察组23.5个月(HR 0.48;95%CI 0.41-0.55);中位随访79.5个月时来那度胺组中位总生存未达到 vs 安慰剂或观察组86.0个月(HR 0.75;95%CI 0.63-0.90;P=.001)。

要点

  • 来那度胺维持较安慰剂或观察显著延长无进展生存(HR 0.48;95%CI 0.41-0.55)
  • 来那度胺维持较安慰剂或观察显示总生存获益(HR 0.75;95%CI 0.63-0.90;P=.001)
  • 疾病进展前第二原发恶性肿瘤累积发生率来那度胺组高于安慰剂或观察组

核心结论

  • 该荟萃分析显示,与安慰剂或观察相比,新诊断多发性骨髓瘤患者自体干细胞移植后来那度胺维持治疗具有显著总生存获益,并证实无进展生存获益。

研究设计与样本

  • 采用原始来源的患者水平数据与文件对三项随机对照试验(CALGB 100104、GIMEMA RV-MM-PI-209、IFM 2005-02)进行荟萃分析,预设纳入标准为:新诊断多发性骨髓瘤接受自体干细胞移植后来那度胺维持对比安慰剂或观察的随机对照试验,且患者水平数据可获取并已完成主要疗效分析的数据库锁定。
  • 共纳入1208例患者,来那度胺维持组605例,安慰剂或观察组603例。

主要发现

  • 来那度胺组中位无进展生存52.8个月 vs 安慰剂或观察组23.5个月(HR 0.48;95%CI 0.41-0.55)。
  • 全部存活患者中位随访79.5个月时,来那度胺维持组中位总生存未达到 vs 安慰剂或观察组86.0个月(HR 0.75;95%CI 0.63-0.90;P=.001)。
  • 疾病进展前第二原发恶性肿瘤累积发生率来那度胺维持组高于安慰剂或观察组,而疾病进展、死亡或死于骨髓瘤的累积发生率均为安慰剂或观察组高于来那度胺维持组。

关键数值与推荐

  • 来那度胺维持组中位无进展生存52.8个月(HR 0.48;95%CI 0.41-0.55)对比安慰剂或观察组23.5个月。
  • 来那度胺维持组中位总生存未达到(HR 0.75;95%CI 0.63-0.90;P=.001)对比安慰剂或观察组86.0个月,中位随访79.5个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Lenalidomide maintenance therapy after autologous stem-cell transplantation (ASCT) demonstrated prolonged progression-free survival (PFS) versus placebo or observation in several randomized controlled trials (RCTs) of patients with newly diagnosed multiple myeloma (NDMM). All studies had PFS as the primary end point, and none were powered for overall survival (OS) as a primary end point. Thus, a meta-analysis was conducted to better understand the impact of lenalidomide maintenance in this setting. Patients and Methods The meta-analysis was conducted using primary-source patient-level data and documentation from three RCTs (Cancer and Leukemia Group B 100104, Gruppo Italiano Malattie Ematologiche dell'Adulto RV-MM-PI-209, and Intergroupe Francophone du Myélome 2005-02) that met the following prespecified inclusion criteria: an RCT in patients with NDMM receiving ASCT followed by lenalidomide maintenance versus placebo or observation with patient-level data available and achieved database lock for primary efficacy analysis. Results Overall, 1,208 patients were included in the meta-analysis (605 patients in the lenalidomide maintenance group and 603 in the placebo or observation group). The median PFS was 52.8 months for the lenalidomide group and 23.5 months for the placebo or observation group (hazard ratio, 0.48; 95% CI, 0.41 to 0.55). At a median follow-up time of 79.5 months for all surviving patients, the median OS had not been reached for the lenalidomide maintenance group, whereas it was 86.0 months for the placebo or observation group (hazard ratio, 0.75; 95% CI, 0.63 to 0.90; P = .001). The cumulative incidence rate of a second primary malignancy before disease progression was higher with lenalidomide maintenance versus placebo or observation, whereas the cumulative incidence rates of progression, death, or death as a result of myeloma were all higher with placebo or observation versus lenalidomide maintenance. Conclusion This meta-analysis demonstrates a significant OS benefit and confirms the PFS benefit with lenalidomide maintenance after ASCT in patients with NDMM when compared with placebo or observation.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. McCarthy PL, Holstein SA, Petrucci MT, et al. Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. J Clin Oncol. 2017. PMID: 28742454. doi:10.1200/JCO.2017.72.6679

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。